Skip to content

Role of yoga therapy against tuberculosis in people living with HIV infection

Role of yoga therapy against tuberculosis in people living with HIV infection: a randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN74208821
Enrollment
1800
Registered
2021-06-28
Start date
2020-04-01
Completion date
Unknown
Last updated
2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of tuberculosis in people living with HIV infection Infections and Infestations Tuberculosis

Interventions

Eligible People Living with HIV (PLHIV) are allocated to the interventional group and the control group by a simple random allocation. This is done by an independent statistician with the help of a co

Sponsors

Public Health Foundation of India
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age 18 - 65 years irrespective of gender 2. Documented HIV diagnosis 3. PLHIV on antiretroviral treatment and stable 4. Received or completed isoniazid prophylaxis therapy 5. Physically fit to perform yoga therapy as self-assessed 6. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Pregnant 2. Seriously ill or moribund PLHIV 3. Practicing yoga therapy >150 minutes/week 4. COVID-19 positive patients

Design outcomes

Primary

MeasureTime frame
1. Occurrence of tuberculosis among PLHIV, diagnosed by Nucleic Acid Amplification test (NAAT), or sputum smear microscopy or chest X-ray when a PLHIV has a presumptive TB as evident by positive 4S symptom screening consisting of cough, fever, weight loss or night sweat, presence of any one irrespective of duration. 2. CD4 T cell count measured by flow cytometry methods at baseline, 6, 12, 18, and 24 months 3. Viral load measured using real time PCR at baseline, 6, 12, 18, and 24 months

Secondary

MeasureTime frame
1. Proportion of opportunistic infections other than tuberculosis, measured by taking clinical history at baseline, 6,12, 18 and 24 months 2. Treatment outcome of the diagnosed TB cases amongst PLHIV, measured by sputum smear microscopy at the end of the intensive phase of anti TB treatment and at the end of continuation phase of anti TB treatment

Countries

India

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 7, 2026